Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
Email Facebook Twitter Google+ LinkedIn Comments

Li-Cor Biosciences

Feb 2010
Li-Cor Biosciences of Lincoln, Neb., and Spectros Corp. of Portola Valley, Calif., have announced a nonexclusive licensing and supply agreement to couple the former company’s IRDye 800CW to the latter’s targeted biomarkers. Additionally, the companies have agreed to develop targeted fluorescent contrast agents for real-time imaging and treatment of prostate and ovarian cancer.

The emission of light or other electromagnetic radiation of longer wavelengths by a substance as a result of the absorption of some other radiation of shorter wavelengths, provided the emission continues only as long as the stimulus producing it is maintained. In other words, fluorescence is the luminescence that persists for less than about 10-8 s after excitation.
agentsAmericasbiomarkersBiophotonicsBusinesscancerfluorescenceFluorescent Contrast AgentsimagingIRDye 800CWLi-Cor Bioscienceslicensingovarian cancerprostateRapidScanreal-time imagingSpectros agreement

Terms & Conditions Privacy Policy About Us Contact Us
back to top
Facebook Twitter Instagram LinkedIn YouTube RSS
©2018 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA,

Photonics Media, Laurin Publishing
x Subscribe to BioPhotonics magazine - FREE!
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.